: Merck to buy Prometheus Biosciences for $10.8 billion
Merck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.
: Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or...
The Escape Home: Everything you need to know as a first-time homebuyer
Purchasing a home — especially in this market — can seem like a daunting task.
Market Snapshot: Why 5% interest rates might not derail the stock market or the U.S. economy
'A 5% interest rate is not going to break the market,' says Ben Snider, managing director, U.S. portfolio strategy at Goldman Sachs Asset Management.
Earnings Watch: Tesla, Netflix earnings due: Cheaper cars, cheaper content, more workout videos, as ‘earnings recession’ seems likely
Netflix, Tesla, banks and credit-card companies report in the week ahead.
: What the Supreme Court’s decision to let $6 billion in student-loan relief move forward means for borrowers
The justices knocked down three schools' request to stop a settlement between hundreds of thousands of borrowers and the Department of Education
Washington Watch: Social Security’s expected shortfall sparks debate over tax increases
Rising income inequality undermines program’s ability to pay future retirement benefits, experts say
: The ‘super surge’ of money market funds is on with yields over 4.6% luring savers. Here’s what you need to know.
‘This is far from normal’: Bank failures have triggered a cash stampede into money funds, but there are complex trade-offs to consider.
Bitcoin vs Ethereum: which one is a better investment?
Scott Melker shares his view on Bitcoin and Ethereum. He also discussed ETH’s recent Shanghai upgrade. BTC and ETH are currently up about 80% for...